Accéder au contenu
Merck
Toutes les photos(1)

Documents

1448901

USP

Mupirocine

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

Acide pseudomonique, BRL 4910A, Ester 8-carboxyoctylique de l’acide 5,9-anhydro-2,3,4,8-tétradésoxy-8-[[3-(2-hydroxy-1-méthylpropyl)oxiranyl]méthyl]-3-méthyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-énonique

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C26H44O9
Numéro CAS:
12650-69-0
Poids moléculaire :
500.62
Numéro MDL:
MFCD01711620
Code UNSPSC :
41116107
ID de substance PubChem :
329750503
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

mupirocin

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

[H][C@@]1(CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O)C[C@@H]2O[C@@]2([H])[C@@H](C)[C@H](C)O

InChI

1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1

Clé InChI

MINDHVHHQZYEEK-HBBNESRFSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Mupirocin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Actions biochimiques/physiologiques

Antibiotique ; inhibe l′isoleucyl-tRNA synthétase (IRS).

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Fusidic acid European Pharmacopoeia (EP) Reference Standard

Y0001411

Fusidic acid

Fluticasone Propionate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1702

Fluticasone Propionate

Tobramycine Aminoglycoside antibiotic

Sigma-Aldrich

T4014

Tobramycine

Mucin from bovine submaxillary glands Type I-S

Sigma-Aldrich

M3895

Mucin from bovine submaxillary glands

BSM Agar suitable for microbiology, NutriSelect® Basic

Millipore

88517

BSM Agar

Nystatin powder, BioReagent, suitable for cell culture

Sigma-Aldrich

N6261

Nystatin

M E H Jaspers et al.
Burns : journal of the International Society for Burn Injuries, 40(8), 1570-1574 (2014-04-02)
Staphylococcus aureus wound colonization frequently occurs in patients with burns and can cause impaired wound healing. Nasal mupirocin application may contribute to the reduction of burn wound colonization of endogenous origin, whereas colonization by the exogenous route can be reduced
Kevin B Laupland et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37(7), 933-938 (2003-09-18)
Most Staphylococcus aureus infections are endogenously acquired, and treatment of nasal carriage is one potential strategy for prevention. We critically appraised the published evidence regarding the efficacy of intranasal mupirocin for eradication of S. aureus nasal carriage and for prophylaxis
I Eltringham
The Journal of hospital infection, 35(1), 1-8 (1997-01-01)
Mupirocin has become the topical agent of choice for the elimination of methicillin-resistant Staphylococcus aureus (MRSA) carriage. The increased use of this antibiotic has been followed by reports of outbreaks due to MRSA with both low- and high-level resistance. Whilst
Gaosi Xu et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 25(2), 587-592 (2009-08-15)
Recently, there have been increasing concerns about the emergence of mupirocin resistance and increased infections due to lowered inhibition of Staphylococcus aureus. We conducted this systemic analysis to find out whether the application of mupirocin was effective for the prevention
J S Bertino
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 54(19), 2185-2191 (1997-10-23)
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of mupirocin are reviewed. Mupirocin is a naturally occurring antibiotic produced by submerged fermentation of Pseudomonas fluorescens. It inhibits bacterial protein synthesis by binding reversibly and specifically to isoleucyl-tRNA
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique